Literature DB >> 18591575

Apathy associated with Alzheimer disease: use of dextroamphetamine challenge.

Krista L Lanctôt1, Nathan Herrmann, Sandra E Black, Michelle Ryan, Lana S Rothenburg, Barbara A Liu, Usoa E Busto.   

Abstract

OBJECTIVE: To assess the role of the dopaminergic brain reward system (BRS) in apathy associated with Alzheimer disease (AD).
DESIGN: BRS function was probed in 20 AD patients using dextroamphetamine (d-amph) challenge. After baseline behavioral testing, patients were given a single 10 mg dose of d-amph. The time course of the subjective response to d-amph was assessed at hourly intervals for 4 hours.
SETTING: Three outpatient dementia clinics associated with a university-affiliated hospital. PARTICIPANTS: Twenty AD patients aged 77 +/- 8 years with Neuropsychiatric Inventory (NPI) apathy scores of 3.4 +/- 3.5 and Mini-Mental State Examination scores of 20.4 +/- 5.1. MEASUREMENTS: Patients were classified as apathetic based on an NPI apathy subscore of > or =4. Apathy severity was assessed using the Apathy Evaluation Scale (AES). The subjective and behavioral responses to d-amph were assessed using computerized versions of the Addiction Research Centre Inventory (ARCI), Profile of Mood States and Connor's Continuous Performance Task.
RESULTS: Repeated measures ANOVA revealed a significant interaction between the presence of apathy and the peak subjective response to d-amph on the ARCI, such that while nonapathetic AD patients were responsive to the rewarding effects of d-amph, apathetic patients were not (F(1,17) = 4.93, p = 0.04). Continuous AES scores were predicted by peak ARCI positive effects scores and baseline overall behavioral disturbances (NPI total) in a backward linear regression analysis using the entire study sample (F(2,17) = 10.00, p = 0.01, R(2) = 0.49).
CONCLUSIONS: Apathy in AD is associated with a blunted subjective response to d-amph, which may be indicative of dysfunction in the BRS.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18591575     DOI: 10.1097/JGP.0b013e318170a6d1

Source DB:  PubMed          Journal:  Am J Geriatr Psychiatry        ISSN: 1064-7481            Impact factor:   4.105


  13 in total

1.  Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo-controlled trial.

Authors:  Paul B Rosenberg; Krista L Lanctôt; Lea T Drye; Nathan Herrmann; Roberta W Scherer; David L Bachman; Jacobo E Mintzer
Journal:  J Clin Psychiatry       Date:  2013-08       Impact factor: 4.384

2.  Neuropsychiatric symptoms in Alzheimer disease and related disorders: why do treatments work in clinical practice but not in the randomized trials?

Authors:  Helen Lavretsky
Journal:  Am J Geriatr Psychiatry       Date:  2008-07       Impact factor: 4.105

3.  Neuropsychiatric symptoms in Alzheimer's disease.

Authors:  Constantine G Lyketsos; Maria C Carrillo; J Michael Ryan; Ara S Khachaturian; Paula Trzepacz; Joan Amatniek; Jesse Cedarbaum; Robert Brashear; David S Miller
Journal:  Alzheimers Dement       Date:  2011-09       Impact factor: 21.566

Review 4.  Reward processing in neurodegenerative disease.

Authors:  David C Perry; Joel H Kramer
Journal:  Neurocase       Date:  2014-01-13       Impact factor: 0.881

5.  The Roles of Apathy and Depression in Predicting Alzheimer Disease: A Longitudinal Analysis in Older Adults With Mild Cognitive Impairment.

Authors:  Myuri Ruthirakuhan; Nathan Herrmann; Danielle Vieira; Damien Gallagher; Krista L Lanctôt
Journal:  Am J Geriatr Psychiatry       Date:  2019-02-07       Impact factor: 4.105

6.  Effect of methylphenidate on attention in apathetic AD patients in a randomized, placebo-controlled trial.

Authors:  Krista L Lanctôt; Sarah A Chau; Nathan Herrmann; Lea T Drye; Paul B Rosenberg; Roberta W Scherer; Sandra E Black; Vijay Vaidya; David L Bachman; Jacobo E Mintzer
Journal:  Int Psychogeriatr       Date:  2013-10-29       Impact factor: 3.878

Review 7.  Principles and management of neuropsychiatric symptoms in Alzheimer's dementia.

Authors:  Milap A Nowrangi; Constantine G Lyketsos; Paul B Rosenberg
Journal:  Alzheimers Res Ther       Date:  2015-01-29       Impact factor: 6.982

8.  Serum homocysteine levels are correlated with behavioral and psychological symptoms of Alzheimer's disease.

Authors:  Hyun Kim; Kang Joon Lee
Journal:  Neuropsychiatr Dis Treat       Date:  2014-10-03       Impact factor: 2.570

Review 9.  Drug Development in Alzheimer's Disease: The Contribution of PET and SPECT.

Authors:  Lieven D Declercq; Rik Vandenberghe; Koen Van Laere; Alfons Verbruggen; Guy Bormans
Journal:  Front Pharmacol       Date:  2016-03-31       Impact factor: 5.810

10.  The Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): study protocol for a randomized controlled trial.

Authors:  Roberta W Scherer; Lea Drye; Jacobo Mintzer; Krista Lanctôt; Paul Rosenberg; Nathan Herrmann; Prasad Padala; Olga Brawman-Mintzer; William Burke; Suzanne Craft; Alan J Lerner; Allan Levey; Anton Porsteinsson; Christopher H van Dyck
Journal:  Trials       Date:  2018-01-18       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.